Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer
Eligibility Criteria
Inclusion Criteria: Patients with histologically proven non-small cell lung cancer Stage I to IIIA. Inoperable lung cancer because of poor respiratory lung function, or other medical reasons, as determined by the thoracic surgeon. PS < 2 Age > 18 years Life expectancy of > 12 weeks Normal hematologic, liver, and renal function No metastatic disease as determined by CT-PET scanning and bone scan. No brain metastasis by MRI No contraindication to radiotherapy Exclusion Criteria: Patients with uncontrolled CNS metastases. Active systemic infection. Serious, uncontrolled intercurrent medical or psychiatric illness. Secondary active primary malignancy. Inability to comply with requirements of the study. Any metastases outside of the mediastinum Histologically positive pleural or pericardial effusion Any chemotherapy within five years prior to enrollment on this protocol Prior radiotherapy administered to the chest Women who are pregnant or lactating FEV1 < 1 liter/minute
Sites / Locations
- University of New Mexico